Patents are legal documents drawn up by inventors and lawyers and granted by various patent offices around the world, to protect the inventors' intellectual property. The short description accompanying each patent in this Patents section is therefore taken from the legal document as is, with minor corrections for Greek symbols and obvious spelling errors. The patents included in this section may be for material products (defensins or defensin-like peptides or nucleic acid sequences, synthetic or natural) or for novel methods of detecting, quantitating, synthesizing, or delivering antimicrobial peptides/nucleic acid sequences in general. The curators' criterion for inclusion in this section is broader for novel methods than for material products, in the hope that these methods may in future be similarly applied to defensins.

Patents in which the defensins or defensin-like material products and methods as above are not novel, such as biomarker sets containing unmodified defensin or defensin-like peptides or oligonucleotides, are excluded from this section. The exception to such exclusions is where the patent provides other novel defensin-related material products or methods in addition to those non-novel of the biomarker set itself. This exclusion is because the reasonable presence of defensin or defensin-like sequences or indeed any other sequences in patented biomarker sets is necessarily attributed to some prior discovery of disease state correlation with such sequences. The curators have observed therefore that the novel discovery in biomarker-related patents is often the method of biomarker array analysis and validation as well as its resultant implications for diagnostics and prognostics. The expert evaluation of such biomarker analysis and validation is well outside the scope of the Defensins Knowledgebase. The reader is respectfully referred to a biomarker database specific to the disease to perform his own assessment of the validity of the biomarker.

Methods not pertaining to the antimicrobial activity of defensins, but where defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences are suggested in some unambiguous detail to play a useful role in the method, with or without supporting experimental evidence, are included as well in this section. Patents in which natural defensins are up/downregulated in a clearly defined signal transduction pathway as a result of the unrelated patented novel compound or method are also included. And lastly, all patents showing experimental work done with defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences, where such peptides or nucleic acid sequences are not the experimental controls, are included without exception.

The data in this section have been extracted from the academic version of SciFinder Scholar 2007 and from public Google search - a wide range of defensin-related patents are included.


Results 121 - 130 of 333

<< Previous | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | Next >>

Last updated: 20th February 2008

Patent No.: US 6759529
Plant-gene promoter and methods of using the same.
Applicant: Misra S, Chattai M (2004)
The invention provides promoters from Douglas-fir genes encoding metallothionein-like proteins. Also provided are deletions and variants of such promoters. The promoters are useful for, among other things, directing developmental-specific expression of transgenes.

Patent No.: US 6753407
Antimicrobial peptides isolated from fish.
Applicant: Noga EJ, Silphaduang U (2004)
Antimicrobial peptides (endobiotic peptides), isolated from fish are described. Such endobiotic peptides may be isolated as 22 amino acid peptides having molecular weights of about 2500 Da from the gills of hybrid striped bass (Morone saxitilis x Morone chrysops). Antibodies that bind such peptides and methods of using such peptides are also described.

Patent No.: US 6747007
Antimicrobial peptides and methods of use thereof.
Applicant: Hancock REW, Zhang L (2004)
A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO:3), RRWCFRVCYKGFCRYKCR (SEQ ID NO:4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO:11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.

Patent No.: US 6743769
Antimicrobial peptides and derived metapeptides.
Applicant: Yeaman MR, Shen AJ (2004)
The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.

Patent No.: US 6740643
Compositions and methods for drug delivery using amphiphile binding molecules.
Applicant: Wolff JA, Hagstrom JE, Monahan SD, Budker V, Rozema DB, Slattum PM (2004)
The present invention relates to the delivery of desired compounds (e.g., nucleic acids) into cells using noncovalent delivery systems which include complexing nucleic acids, amphipathic binding agents, and amphiphiles.

Patent No.: US 6719984
Composition and method for immunomodulation in mammals.
Applicant: Ansley DR (2004)
This invention relates to compositions and processes utilized to modulate the immune system of mammals. More particularly, the present invention relates to the use of low molecular weight substantially immunoglobulin free fractions isolated from mammals to induce a stimulated immune response in mammals.

Patent No.: US 6716819
Use of xylitol to reduce ionic strength and activate endogenous antimicrobials for prevention and treatment of infections.
Applicant: Welsh MJ, Zabner J (2004)
A method for killing infectious microbial cells by exposing the microbial cells to endogenous antimicrobial compounds. Activation of the antimicrobials is achieved by addition of low permeability, non-ionic osmolytes to lower ionic strength in body fluids where the antimicrobials have been previously suppressed by alteration of ionic transport (increase in salt concentration). The method can be used to treat cystic fibrosis. Cystic fibrosis causes elevated salt concentrations in the airway surface liquid (ASL) occur due to the impaired chloride transport across the epithelia. Xylitol has been found to be an effective low permeability, non-ionic osmolyte for use in the present invention.

Patent No.: US 6716434
Composition and method for immunostimulation in non- mammalian vertebrates.
Applicant: Ansley DR, Willeford KO (2004)
This invention relates to compositions utilized to modulate the immune system of non-mammalian vertebrates. More particularly, the present invention relates to the use of low molecular weight substantially immunoglobulin free fractions isolated from mammals to induce a stimulated immune response in non-mammalian vertebrates.

Patent No.: US 6713605
Synthetic peptides that inhibit leukocyte superoxide anion production and/or attract leukocytes.
Applicant: Blecha F, Shi J (2004)
Methods of inhibiting leukocyte O.sub.2.sup.- production and attracting leukocytes using specific peptides are disclosed. These peptides include the proline-arginine (PR)-rich antimicrobial peptide known as PR-39 and truncated analogs thereof. These peptides can be used as medicaments that fight infection by attracting leukocytes to a wound site, yet restrict tissue damage at the wound site caused by excessive oxygen radicals produced by these leukocytes.

Patent No.: US 6713453
Fibrin/fibrinogen-binding conjugate.
Applicant: Redl H, Fuerst W, Kneidinger R, Helgerson SL, Looker D, Inman EM, Richards JP, Wong C (2004)
A fibrin/fibrinogen binding conjugate for forming a depot for the sustained release of a pharmaceutically active substance from a fibrin clot. The conjugate comprises a fibrin/fibrinogen binding moiety bound to a pharmaceutically active substance either directly or via an intervening substance capturing moiety such as an antibody. The conjugate can also be a recombinant fusion protein comprising a fibrin/fibrinogen binding moiety such as VEGF.sub.165 C-terminal domain fused to a wound-healing substance such as leptin.